Podcasts about dako

Poco podían sospechar los pescadores de estas islas tropicales que el carácter de su mar, esas duras olas que a menudo complican la faena a bordo de sus bangkas, acabarían colocándolos en el mapa de los mejores destinos del mundo para practicar surf. La isla de Siargao, el malecón Cloud 9 y el pueblo de General Luna se han transformado en una meca de la tabla encerada. Pero hay mucho más: los primeros turistas internacionales comenzaron a divulgar los encantos naturales de Caraga, una de las regiones más inexploradas de Filipinas. El coordinador cultural de su embajada, Joshua Miguel Hermosa Orille, nos invita a practicar island hopping; es decir, a navegar saltando entre islitas como Guyam, Dako o Naked Island. Contamos también con la compañía de Ane Corta, donostiarra residente desde hace varios años en Siargao y gran conocedora de la escena surfera de esta provincia al noreste de Mindanao. El guía Patrick June Ceniza, natural de Caraga, y la propietaria de la agencia de viajes Kara Tours, Jennifer Nanayakkara, nos permiten descubrir otras partes de la región como la ciudad de Surigao, la marisma de Agusan y los paisajes del archipiélago de Dinagat. Laura Pascual, directora de Woola Filipinas, nos muestra algunas de sus mejores playas blancas, lagos turquesas y montes tapizados de vegetación, incluido un bosque de bonsáis. La coautora de la web ViajarPorFilipinas.com, Claudia Rodríguez, completa nuestra ruta con estimulantes visitas: las cataratas Tinuy-An, el río Encantado o los pueblos costeros de Salvación y Lanuza. Recogemos también las impresiones de una viajera, Lola Sánchez-Infante.Histórico de emisiones:11/12/21Escuchar audio

JCO PO author Dr. Samuel J. Klempner shares insights into his JCO PO article, “PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity across 28-8, 22C3, and SP263 assays”. Host Dr. Rafeh Naqash and Dr. Klempner discuss assessing the analytical comparability of three commercially available PD-L1 assays and two scoring algorithms used to assess PD-L1 status in gastric cancer samples. TRANSCRIPT  Dr. Abdul Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Abdul Rafeh Naqash, Social Media Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center. Today we are excited to be joined by Dr. Samuel J. Klempner, Director of Gastro Esophageal Medical Oncology and Assistant Professor at Harvard Medical School Mass Gen Cancer Center and author of the JCO Precision Oncology article, “PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays.” At the time of this recording, our guest disclosures will be linked in the transcript. Dr. Klempner, welcome to our podcast and thanks for joining us today.  Dr. Samuel J. Klempner: Happy to be here. Thanks for having me. Dr. Abdul Rafeh Naqash: For the sake of this podcast, we'll be using our first names. So, Sam, it was great to see you at ASCO recently, where I believe you presented these data as an abstract as well. Dr. Samuel J. Klempner: Yes, we had a poster presentation for this paper, which was published in parallel with the meeting. Dr. Abdul Rafeh Naqash: Congratulations, and I'm very happy that you chose JCO PO as the destination for these data. So we're going to be talking about a lot of different things today in the context of gastric cancer, which I know you treat very often in your clinic. So could you tell us what the treatment landscape for advanced gastric cancer currently is? Because that goes into the context of why I believe you and your colleagues went ahead with this project.  Dr. Samuel J. Klempner: Yeah, happy to. As you know, unfortunately, half or more of our patients, by the time they come to medical attention for a gastric or GE junction or esophageal adenocarcinomas, unfortunately have advanced disease, often metastatic at presentation. So we have this large population of patients with advanced disease, and over the last couple years, we've actually made some substantial advances in the management and survival of this population. This has been mainly driven by biomarker selection, whether it be adding immunotherapy on top of HER2 therapy, whether it be testing for claudin and seeing the results with claudin directed therapies. And perhaps the vast majority of patients are potentially eligible for immune checkpoint inhibitors. We've seen several phase three trials, perhaps highlighted by CheckMate 649, KEYNOTE 859, rationale studies confirming that there are populations of patients who derive significant survival advantages from the addition of anti PD-1 on top of chemotherapy. So the landscape has really evolved into a biomarker directed world, which is exactly what we hope, because ultimately, the goal is, of course, to match patients with the best drugs at the right time. And that's really the background of where this analytical effort came from.  Dr. Abdul Rafeh Naqash: Thank you for giving us that overview. Going to the second part, which, as you mentioned in your initial overview about the role of immunotherapy, and as we all know, immunotherapy has changed the treatment landscape for a lot of different tumor types. And as clinicians, we often see or ask, what is the PD-L1 positivity for, let's say, lung cancer, which is what I treat, and gastric cancer, which is what you treat. Some of the nuances that we don't necessarily go into when we're looking at those reports is the combined positivity score, the tumor proportion score, or the tumor area positivity. Could you give us an understanding, for the sake of our audience or for the sake of our trainees who might be listening to this podcast, what the CPS, or what the TAP  mean and where they are used in the treatment landscape for biomarker selection in the context of gastric cancer? And how do you approach the different cutoffs for CPS when you're treating an individual in the standard of care setting for gastric cancer? Dr. Samuel J. Klempner: For sure, happy to. So I think eventually it all comes back to patients. When we're sitting in a clinic room with the patient, we want to be able to have features about the tumor that's going to tell us if a therapy is more or less likely to work, maybe if there's a prognostic implication so we have predictive and prognostic biomarkers. And PD-L1 expression does not appear to be particularly prognostic, but it does appear to be predictive of benefit from immune checkpoint inhibitors. Therefore, all of the phase 3 trials that we've seen in some way have linked the biomarker expression to outcomes, whether it's the primary endpoint, whether it's post hoc retrospective analyses, etc. What we've seen is that all of these phase 3 trials have largely used different antibodies to define PD-L1 strata within the trial. So whether that's 22C3,  whether it's 28-8, whether it's 263, those are the predominant antibody clones used to examine PD-L1 expression in tumor samples. And it's been pretty clear across these large phase 3 trials that there is a trend with increasing PD-L1 expression and increasing magnitude of benefit. We see this in the improved hazard ratios in the CPS greater than five or greater than ten versus less than one, etcetera.  However, the scoring systems have varied. There is TPS tumor positivity, which only accounts for tumor cells. There is combined positive score, which accounts for tumor cells and mononuclear infiltrates and involves counting cells. And then perhaps the most recent one is the tumor area positivity, which is essentially a non counting method to look broadly at the area of the sample that is expressing PD-L1. It was on this background that we said, is there analytical concordance among the main antibodies? Our work does not address whether there is difference in clinical outcomes between testing 28-8 and 22C3 and SP263. It is simply a pure analytical comparison of the three antibodies. Is a CPS 5, when you call it by 28-8, somewhat agreeable to a TPS or a TAP greater than five with the same antibody and with a different antibody. So we felt that this was kind of a question that hadn't really been fully addressed in the field and may help contextualize results for clinicians and ultimately cross trial comparisons.  Dr. Abdul Rafeh Naqash: Thank you for that explanation. And you bring forth a very important question. And I remember this example of a patient with lung cancer who had tissue NGS done, and they had a limited gene panel with PD-L1 testing sent that showed a PD-L1 of close to 15 or 20%, and then another NGS panel with a different antibody, suggesting that they had a PD-L1 of close to 60-70%, which significantly changes the overall approach for treatment in the context of blood cancer. Is that something that you experience in gastric cancer also, in terms of variability for CPS, determining what treatment combinations you might be able to put an individual patient on? Dr. Samuel J. Klempner: It's rare that we have samples at any institution tested in multiple methods, but these types of papers and others had looked at some stuff similar and prior to our publication, but we know that there is both spatial heterogeneity. So if you test a tumor versus metastasis, you may have different PD-L1 scoring even in regions of large samples, like surgical resections, there will be some intra tumor heterogeneity in regions of expression. And then we also know that sometimes after therapy, for example, post radiation, there's some data that at the time of surgery, the PD-L1 expression may be higher than what the presurgical sample was. So there's a lot of variables that are factored in. But one thing that wasn't really well known is, across the standard antibodies, how well is the inter assay comparison? There had been some work from a group in Singapore, a very nice paper suggesting that at the higher cut points, the agreement was pretty good across the assays, CPS greater than 5 and greater than 10, and maybe slightly less so at the lower. They had used a different method, which was not really what is standard, and they had used multiplex immunofluorescence or IHC. This is not a validated method for PD-L1 scoring. So that was an open question, sort of. Although they laid a very important piece of data down, we wanted to use the most standard assays and essentially do a very similar analysis, but using the standard scoring criteria. Dr. Abdul Rafeh Naqash: Very interesting. So, could you walk us through the approach of how you looked at this question, what kind of samples you used and what kind of testing algorithms you implemented to look at the cross validation of these three different antibodies? Dr. Samuel J. Klempner: The antibodies were chosen primarily because those are the standard ones that either have companion diagnostics or have been used most commonly in phase 3 trials. So 22C3 has most commonly been linked to pembrolizumab, 28-8 to nivolumab, and 263 used with Roche and Genentech trials primarily. And so we selected the antibodies based on the common use. We selected the scoring systems of CPS and TAP, again based on the most commonly used and validated scoring algorithms in gastric cancer. And then, although most patients in clinic and metastatic disease present with biopsy samples from the primary tumor, there may be some limitations in biopsy samples in terms of small amount of material and ability to reliably count 100 cells, etc., for CPS. So we actually use surgically resected samples from a commercial biobank, 100 samples, and essentially 28-8 was really the reference. And we picked samples that, using 28-8 CPS PD-L1 expression represented the entire spectrum, meaning we had CPS less than 1, we had greater than 1 and less than 5, greater than 5 and less than 10, and greater than 10, so that we could compare across these different strata, because those are the most common strata that have been used in clinical trials and linked to magnitude of benefit. Dr. Abdul Rafeh Naqash: And something that, interestingly, I see here when we go to some of the results, and I'm pretty sure you'll talk about the concordance, is the correlation coefficient seems to increase as the percentage positivity increases for a certain antibody. Could you try to help us understand why that might be the case? Is it because it's easier for the pathologist to look at the slide when there is a certain level of positivity that crosses a certain threshold? Or could there be some other factors that are not well understood. Dr. Samuel J. Klempner: Yeah, it's a totally good question, and I think it's something that's seen in other IHC biomarkers as well. If you look at HER2, you'll see some similar trends. The agreement at IHC 3+ is pretty good and greater than it is at lower cut points. And having talked to multiple pathologists, and I'm not a pathologist, we had three pathologists scoring all of these samples, and essentially, it's what you might expect. It is just easier when there's a lot of the marker. It is easier to judge the high extremes of the strata. So the agreement at greater than 10 is quite good, and this has already been shown by others. It's just an easier thing to score for anyone. The agreement is better across all of the assays at higher cut points, whether it's TAP greater than 10% or CPS greater than 10%. And you can see that pretty clearly in our data, and it's also been shown in other data sets looking at roughly similar questions in other tumor types.  Dr. Abdul Rafeh Naqash: Going to the interesting results that you have in this paper, could you highlight for us some of the important findings that you had and put them into context of what their clinical implications may be? Dr. Samuel J. Klempner: Yeah, I think I'll start with the clinical implications so that what clinicians, and we're both clinicians, what we want to know is, if I have a report that says the CPS is greater than 1 and it's done with a 22C3 test, is that also likely to be greater than one if it had been done with a 28-8 test or scored with a different algorithm - CPS versus TAP? So, essentially, some degree of confidence on the interchangeability between the assays themselves, that is really the clinical implication. And so, to accomplish this, we set out to basically do the comparisons you'd have to do to convince yourself that that is true. So you take samples against a reference range, in this case, across the PD-L1 strata, you pick a reference test, in this case, 28-8, you have one pathologist be the start, and then you compare other pathologists against each other and that person, and you look. And in the pathology literature, they have strata of agreement which tend to go from poor, moderate, good to excellent. And these are sort of accepted standards in the pathology world about inter reader agreement. So between one pathologist and another, and things that are moderate or good are considered essentially acceptable at interchangeable levels.  And so, as you suggested, at the higher cut points, the agreement is very good. The clinical interpretation of that is that if you get a TAP greater than 10% scored on a 22C3 antibody on a Dako staining system, you can feel relatively confident that that would also be called a TAP or a CPS greater than 10 by a 28-8 antibody, suggesting there is good agreement between the two antibodies at that cut point. As you move down, there is a little bit less agreement, and that is consistent with what's been shown before. But in our data set, the agreement was still pretty good across all three of the antibody clones, even at the lower cut point, so greater than 1% for TAP or CPS greater than 1. And that provides, I think, some reassurance to clinicians that whatever test their own pathology lab is using, if it's one of these three assays, they can provide some degree of confidence that what they're seeing would be similar to what they were seeing if it had been done with another test. Dr. Abdul Rafeh Naqash: I think that that is very important, because even though we do want broad testing in general for metastatic tumors, as you probably will agree with, but there's a lot of practices still that institutions tend to do their own testing with limited gene panels or even IHCs. So I think to put that in the context of your study, as you said, if you have a certain antibody that is positive, as you've shown, then that also likely means that with another antibody that your institution may not test for, it's likely the tumor sample is likely going to be positive at a similar level.  So I think you also used digital pathology as part of this project, even though that may not be the most important aspect. As we move slowly and steadily towards artificial intelligence and machine learning, could you tell us how you incorporated the digital assessments and how you utilize them to correlate with the pathologist assessment and the futuristic perspective of how we could eventually try to incorporate digital pathology assessments for this kind of staining approach, which might limit interobserver operability differences as well as time constraints? Dr. Samuel J. Klempner: I hope I can do this part justice, because, again, I'm not a pathologist. But the digital imaging analysis was really essentially used as a quality check and verification tool in our own paper. Our intent was not to establish DIA directly as a superior methodology to TAP or CPS, but simply to provide ourselves some degree of confidence in the staining pattern and distribution across the three assays, and whether or not this would generate significant differences in what the PD-L1 score would have been called. And so, the bottom line is, the digital imaging analysis suggested there were very minor differences across the three assays in terms of, like, percent cell positivity, which is one of the main readouts, and the mean difference was actually quite small. So we felt that the digital imaging analysis, which was really considered somewhat exploratory in our own work, supported what we saw with the pathology comparators read in traditional methods. I think it sets somewhat of an initial pilot data benchmark to say that maybe we can think about moving tools like digital imaging analyses forward in terms of PD-L1 scoring approaches in the future. But it does not provide adequate data to say that we can do this now or we have enough samples and enough comparisons to say that, “Hey, for sure, digital imaging is equivalent to pathology reading.” I think that we're getting there and our data supports that that may ultimately be the conclusion, but for us it was really essentially an orthogonal support and sanity check for our traditional approach, which is, of course, a pathologist based scoring. So supportive and suggestive, but not definitively conclusive. Dr. Abdul Rafeh Naqash: Definitely early days for visual pathology assessments, but I think that it's a very rapidly evolving field, and hopefully we'll see more of this in the next few years, as well as incorporating some assessments into clinical trials.  Now, shifting away from your honorary pathologist role as part of this project to your actual role as a clinician investigator/clinician scientist, could you tell us your career trajectory, how you started, how you've self paced yourself, and how you've tried to mentor certain different individuals in your current role? Dr. Samuel J. Klempner: Yeah, I remember my grandfather and other people telling me, just try to leave it a little bit better than you found it. And so that's, I think, a guiding principle. I hope that at the end of my own career, I can leave oncology a little bit better than when I started. I think the best way to do that is to mentor and train the next generation who are going to drive these practices. I started, like many others, personally touched by cancer in my family, which started me on a journey towards oncology, was somewhat frustrated by the lack of options available to my mom, and then became deeply interested in the science and how come we knew so little about cancer, so spent a fair amount of time in labs, and had a really formative experience with Lew Cantley looking at PI3 kinase resistance and signal transduction, and wanted to learn to speak the language and interact with people driving the lab based work. And that's been something I've tried to keep as central to my career as someone who has a very strong translational interest.  And so I try to think of ways that I think we can learn from every single patient and every subgroup. I mean, for example, in our own work here, it's very unclear if there's a biology linked to the different PD-L1 strata. So for example, does a PD-L1 CPS greater than 10 tumor have a very high interferon gene signature? Or are there features of the T cells that are different between a CPS 10 or higher versus a less than 1? So PD-L1 is a biomarker, but is it really telling us about biology? And so these are the types of questions that I try to stimulate in all the residents and fellows and hopefully it will drive translational projects. But I think just having the conversations and asking the questions and talking to people. I mean, I love the ASCO Career Lounge and always try to do that when possible. I know you do the same. I think staying curious is really the thing that I try to remain in life and also in my career and have fun and enjoy with your colleagues. And I think that will make us all better researchers and ultimately translate to better outcomes for our patients, which is, of course, why we all do this. Dr. Abdul Rafeh Naqash: Wonderfully said Sam, thank you so much. Thanks again for choosing JCO PO as the final destination for your work. Hopefully we see more of the similar work that you do in your field in JCO PO. And thank you for talking to us about your journey as well.  Dr. Samuel J. Klempner: Yes, thanks for having me. I'll talk to you sometime soon.  Dr. Abdul Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.     Disclosures Dr. Klempner Stock and Ownership Interests TP Therapeutics Nuvalent, Inc Honoraria Merck Serono Consulting or Advisory Role Atellas Pharma Bristol-Myers Squibb Merck Daiichi Sankyo/UCB Japan Sanofi/Aventis Mersana Exact Sciences Novartis SERVIER AstraZeneca Amgen I-Mab iho Oncology    

Anna Dako,'s book Dances with Sheep: On RePairing the HumanNature Condition in Felt Thinking and Moving towards Wellbeing (Intellect Books, 2023) presents the methodology of Felt Thinking in Movement as an eco-somatic practice inspired by re-thinking nature of being human, as well as contextualises it within wider frameworks of cultural, philosophical and therapeutic viewpoints on wellbeing. Felt Thinking is a self-inquiry practice grounded in somatic movement experience that originates in site-specific and embodied dialoguing between what is felt and what shapes as a responsive thought, as creative movement itself, and which paths ways for ecologically inclusive care for being well with self and other. The book elaborates on creative processes in and with the natural environment in relation to the movers' overall wellbeing and covers creative journeys of opening up to the living agency of Nature itself through the emergent three phases of experiential relatedness in embodied experience of the self. The book presents its original contribution to eco-phenomenology with its ontological principle of embodied relationality in towards and away from movement as a primal gateway to wellbeing and its creative inter-constitution. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Anna Dako,'s book Dances with Sheep: On RePairing the HumanNature Condition in Felt Thinking and Moving towards Wellbeing (Intellect Books, 2023) presents the methodology of Felt Thinking in Movement as an eco-somatic practice inspired by re-thinking nature of being human, as well as contextualises it within wider frameworks of cultural, philosophical and therapeutic viewpoints on wellbeing. Felt Thinking is a self-inquiry practice grounded in somatic movement experience that originates in site-specific and embodied dialoguing between what is felt and what shapes as a responsive thought, as creative movement itself, and which paths ways for ecologically inclusive care for being well with self and other. The book elaborates on creative processes in and with the natural environment in relation to the movers' overall wellbeing and covers creative journeys of opening up to the living agency of Nature itself through the emergent three phases of experiential relatedness in embodied experience of the self. The book presents its original contribution to eco-phenomenology with its ontological principle of embodied relationality in towards and away from movement as a primal gateway to wellbeing and its creative inter-constitution. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/performing-arts

Anna Dako,'s book Dances with Sheep: On RePairing the HumanNature Condition in Felt Thinking and Moving towards Wellbeing (Intellect Books, 2023) presents the methodology of Felt Thinking in Movement as an eco-somatic practice inspired by re-thinking nature of being human, as well as contextualises it within wider frameworks of cultural, philosophical and therapeutic viewpoints on wellbeing. Felt Thinking is a self-inquiry practice grounded in somatic movement experience that originates in site-specific and embodied dialoguing between what is felt and what shapes as a responsive thought, as creative movement itself, and which paths ways for ecologically inclusive care for being well with self and other. The book elaborates on creative processes in and with the natural environment in relation to the movers' overall wellbeing and covers creative journeys of opening up to the living agency of Nature itself through the emergent three phases of experiential relatedness in embodied experience of the self. The book presents its original contribution to eco-phenomenology with its ontological principle of embodied relationality in towards and away from movement as a primal gateway to wellbeing and its creative inter-constitution. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/psychology

Anna Dako,'s book Dances with Sheep: On RePairing the HumanNature Condition in Felt Thinking and Moving towards Wellbeing (Intellect Books, 2023) presents the methodology of Felt Thinking in Movement as an eco-somatic practice inspired by re-thinking nature of being human, as well as contextualises it within wider frameworks of cultural, philosophical and therapeutic viewpoints on wellbeing. Felt Thinking is a self-inquiry practice grounded in somatic movement experience that originates in site-specific and embodied dialoguing between what is felt and what shapes as a responsive thought, as creative movement itself, and which paths ways for ecologically inclusive care for being well with self and other. The book elaborates on creative processes in and with the natural environment in relation to the movers' overall wellbeing and covers creative journeys of opening up to the living agency of Nature itself through the emergent three phases of experiential relatedness in embodied experience of the self. The book presents its original contribution to eco-phenomenology with its ontological principle of embodied relationality in towards and away from movement as a primal gateway to wellbeing and its creative inter-constitution. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/spiritual-practice-and-mindfulness

As Albanian interest in going to the UK shows no sign of abating, I am joined by two Brits-Richard Russell and Carolyn Perry who have made Albania home and are applying for Albanian citizenship. I also tackle recent developments between Kosovo and Serbia with the intervention of the Albanian prime minister, the freefall of the Euro, the arrest of Vangjush Dako and release of Saimir Tahiri, and am joined by Valbona Sulçe to talk about how banning sexism from TV can help tackle the issue of domestic violence in society.

J'ai vendu 300 bouteilles de vin en les faisant passer pour du jus de raisin

Tomáš Zima dopoledne krátce provedl provedl Jana Pokorného po laboratořích 1. lékařské fakulty, kde působí, a bylo vidět, že je tam doma. S velkým zápalem mu ukázal také knihovnu i různé historické knihy. Z Prahy zamířili autem přes serpentiny u obce Žleby do Třemošnice, kde je firma DAKO, výrobce brzd, kterými jsou vybavené třeba i vagony londýnského metra.

Tomáš Zima dopoledne krátce provedl provedl Jana Pokorného po laboratořích 1. lékařské fakulty, kde působí, a bylo vidět, že je tam doma. S velkým zápalem mu ukázal také knihovnu i různé historické knihy. Z Prahy zamířili autem přes serpentiny u obce Žleby do Třemošnice, kde je firma DAKO, výrobce brzd, kterými jsou vybavené třeba i vagony londýnského metra.Všechny díly podcastu Speciál Radiožurnálu můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Cześć! W związku z podpisaniem umowy konsorcyjnej przez warszawską hi GRUPĘ oraz Grupę Eura7 dzisiejszym gościem naszego CEO Łukasza Wołka będzie Marek Szabrański (CEO hi GRUPY). Oficjalne sformalizowanie współpracy to już kolejny etap kooperacji obu podmiotów i wynik wspólnych realizacji na rzecz wielu marek (m.in. Mosso, DAKO czy Edu Bears), o którym więcej możecie przeczytać TUTAJ. Marek Szabrański, jako człowiek będący w branży od 2008 roku, jest skarbnicą wiedzy marketingowej, toteż rozmowa Panów obejmie szerokie spektrum tematyczne. Będzie między innymi o zmianach w kwestii wydatków na reklamę internetową na przestrzeni ostatnich lat, o korzyściach prowadzenia kampanii w internecie i efektywności w przenoszeniu budżetu. Osoby zainteresowane tą tematyką dowiedzą się także o tzn. crawlerach, wskaźniku viewability czy różnicach dzielących rich media od mediów klasycznych oraz komunikację online i offline. Nie zabraknie również odwołań do pioniera nowoczesnego marketingu - Johna Wanamakera i raportów Publicis Groupe oraz IAB POLSKA.Zastanawialiście się kiedyś, dlaczego można powiedzieć, że żyjemy w przyszłości?Przy okazji zachęcamy do zapisów na listopadowy bezpłatny webinar „Jak znaleźć swoje UVP oraz wykorzystać je w content marketingu?”, który odbędzie się 24 listopada (czwartek) o godz. 10:00, a poprowadzi go dla Was nasz Head of PR and Content Marketing Maks Michalczak. Z tego odcinka dowiecie się: Na czym polega partnerstwo Grupy Eura7 z hi GRUPĄ?W czym specjalizuje się hi GRUPA?Jak na przestrzeni ostatnich lat zmieniły się wydatki na reklamę internetową?Czy internet jest medium policzalnym?Jakie korzyści wynikają z prowadzenia kampanii w internecie?Czym są crawlery?Na czym polega wskaźnik viewability?Czym się różnią rich media od mediów klasycznych?Co wpłynęło na zmianę komunikacji rich mediowej na przełomie lat?Czym jest efektywność w przenoszeniu budżetu?Na czym polega różnica w komunikacji online i offline?Czy media społecznościowe są przeznaczone dla wszystkich firm?Z czego wynika sukces w branży marketingowej?Na co pozwala firmie obecność w internecie?W jaki sposób zrobić badanie rynkowe, unikając dużych wydatków?Dołącz do grupy networkingowej podcastu Marketing ludzkim głosem:https://www.facebook.com/groups/MarketingLudzkimGlosem/

Aujourd'hui je passe un Frat Pack avec Odah Sama ! Dans cet épisode on va revenir dans un calme absolu sur sa carrière : études de commerce, début dans le rap & ses battles, la rencontre avec Dako, sa vie de famille avec Emy LTR et leur fils, sa nouvelle carrière dans le stand-up en solo, tout ça et bien plus encore juste en cliquant sur play (c'est pas très compliqué t'as vu)Deux petits jeux, dont le Quizz'art que tu peux retrouver sur les réseaux en vidéo (@alexandrezama) et découvre à la fin de la saison qui sera le grand gagnant (SPOILER : y a rien à gagner)Bon épisode la famille Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

  Fan de Raps Contenders et End Of the Weak, M. Dako et son ami Odah lui proposent depuis des années un mélange d'humour, d'improvisation et de rap.  Parallèlement à leurs nombreuses scènes en France, ils créent la série "Les Fables d'Odah et Dako", diffusée sur Canal Plus, dont ils sont les protagonistes.  Ils sont également capables de développer leurs projets pour le web et de se constituer une solide communauté sur le web. Aujourd'hui, M. Darko est revenu à sa première passion : la musique. Il a commencé le rap à 14 ans. Il s'en est parfois éloigné mais ne l'a jamais lâché. Cette année marquera un tournant avec la sortie de trois EP, plusieurs clips, nombreuses scènes et une présence digitale significative.

Bonjour Pologne! Witamy się dziś w języku Moliera, ponieważ pierwszym tematem tego odcinka Branżowiska są znane targi branżowe, które odbywają się w stolicy Francji. Mowa oczywiście o wystawie Batimat, która odbyła się w dniach 3-6 października. Tegoroczna edycja podzielona była na sześć równoległych obszarów tematycznych, ściśle powiązanych z branżą budowlaną, a jednym z nich była stolarka otworowa. Z polskich swoje stoiska w Paryżu miały m.in. Adams, Akpo, All Windows Group, Dako, Delta, Droma – Sunshade Experts, Drutex, Eko-Okna, Fakro, Globplast, Sanok Rubber Company, Klimas Wkręt-met, Mariola, Splendoor, Sun Winner, Wiśniowski. Jaki wrażenie zrobiła ta impreza na odwiedzających i czy można mówić o sukcesie w przypadku tej edycji? Czy frekwencja dopisała? Dlaczego wiele firm miało mniejsze stoiska niż zazwyczaj na imprezach targowych? Odpowiedzi znajdziecie w tym odcinku podcastu. Drugi temat dotyczy nowego obszaru działalności potentata polskiej branży stolarki, czyli firmy Eko-Okna. Producent z Kornic poinformował, że wybuduje osiedle mieszkaniowe. Projekt realizowany jest pod marką Eko-Invest. Trwają właśnie prace związane z budową osiedla domów jednorodzinnych Zielone Tarasy. Powstanie 28 budynków w zabudowie szeregowej i bliźniaczej. Jak oceniamy ruch Eko-Okien w stronę deweloperki? Przedstawiliśmy też skrót pozostałych informacji, które w ubiegłym tygodniu zostały opublikowane w serwisie ForumBranzowe.com. W Krótkim Przeglądzie Ekonomicznym omówiliśmy z kolei wyniki finansowe takich firm jak: Aluprof, Akzo Nobel oraz Sanok Rubber. Nie zabrakło tez oczywiście Stoll Street, czyli naszej zabawy, w której inwestujemy wirtualne pieniądze w spółki z branży stolarki, które notowane są na Giełdzie Papierów Wartościowych. Na koniec oczywiście wybrzmiał suchar. Miłego słuchania!

Val :  - Champ contre Champ présenté par Akim Omiri   https://www.youtube.com/user/ahquimeprod  - Muscle ton jeu présenté par Odah & Dako  https://www.youtube.com/c/UnibetFrance/videos  - Coupez de Michel Hazanavicius  Musique de fin : Aests - Duck Groove  https://soundcloud.com/aests/duck-groove Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Halo Listener Episode kali ini spesial di ulang tahun Bingkai Karya yang ke 4, Kita akan ngobrol-ngobrol bersama dengan Dako Brand & Communication yang akan bercerita tentang pengalaman paling menajubkan sesuai dengan tema ulang tahun Bingkai Karya Jadi Yuk segera dengarkan sekarang dan jangan lupa dengarkan terus Bingkai Sains setiap hari Kamis, Banana setiap hari Jumat, dan Bingkai Gadis setiap hari sabtu di Channel Podcast Network Bingkai Karya atau kunjungi website kita di www.bingkaikarya.com Supported by EJSC Malang

Dr. Shaalan Beg, of UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and Science 37, discusses hot topics in GI oncology, including KRAS wild-type pancreatic cancer, the SURF-Cohort trial in hepatobiliary cancer, and key studies in gastric cancer featured at the 2022 ASCO Annual Meeting.  Transcript ASCO Daily News: Hello and welcome to the ASCO Daily News podcast. I'm Geraldine Carroll, a reporter for the ASCO Daily News. My guest today is Dr. Shaalan Beg, who is an adjunct associate professor and gastrointestinal (GI) medical oncologist at UT Southwestern Harold C. Simmons Comprehensive Cancer Center.  Dr. Beg also serves as vice president of oncology at Science 37. Dr. Beg will be telling us about key posters in GI oncology that will be featured at the 2022 ASCO Annual Meeting. His full disclosures are on our show notes and disclosures of all guests on the podcast can be found on our transcripts at asco.org/podcasts.  Dr. Beg thanks for coming on the podcast today.  Dr. Shaalan Beg: Thank you so much for having me.  ASCO Daily News: Let's begin with “A multicenter, non-randomized, controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF-Cohort Trial): Analysis of overall survival.” That's Abstract 4095. This study evaluated the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma. So, what are your key takeaways from this study?  Dr. Shaalan Beg: This is a very interesting and timely clinical trial from our investigator colleagues in Japan, Dr. Yamashita, and colleagues, where they evaluated the effectiveness of radiofrequency ablation versus surgery for patients with small hepatocellular carcinomas who have a good liver function.  History is that the best most effective treatment option has always been surgery and we know that ablative techniques like radiofrequency ablation (RFA) or stereotactic radiation can do a good job in controlling the individual cancers, but we don't know what the long-term effects can be in terms of recurrence, free survival, and overall survival.  So, this trial looks to compare RFA or radiofrequency ablation versus surgery for groups of patients who have a good liver function, so a Child-Pugh score of 7 or less, and those who had no lesion greater than 3 centimeters and less than 3 hepatocellular carcinoma (HCC) nodules.  All the people were evaluated by surgeons and hepatologists, to confirm that they would be eligible for both procedures. And then the patients received either 1 of those treatments and they followed them in the long term and found that there was no significant difference between how people who are treated with surgery fared versus RFA.  This is really interesting and practical and timely because the results of these clinical trials can inform our clinical practice today. The median follow-up period was 6.8 years in the surgery group and 6.7 years in the RFA group and the overall survival was not different. Their 5-year overall survival for surgery was 79.7%. And very similar to what they were seeing in both groups.  ASCO Daily News: Excellent! Great to hear some promising developments for this patient population. Well, in Abstract 4026, investigators are suggesting that the choice of PD-L1 immunochemistry assay influences clinical eligibility for gastric cancer immunotherapy. What are your thoughts on this study?  Dr. Shaalan Beg: Yeah! Clinicians, clinical investigators, and even patients have been really confused by the definitions of PD-L1 expression. PD-L1 expression is 1 of our biomarkers for response to immunotherapy and immune checkpoint inhibitors. But the challenge in this field is that there are multiple assays that define various criteria for PD-L1 expression. And if you look at different clinical trials, they look at different definitions of positivity. So, a trial may have 1 plus. Some may have 5 plus percent. Some have 50 plus percent.  So, this group out of Singapore took 362 gastric cancer samples, and they evaluated its PD-L1 expression using the combined positive score or the combined positive score (CPS), the tumor proportion score (TPS), and immune cell expression, and they compared them to see how well all of these performed because what's important to remember is we don't know how interchangeable the different immunohistochemistry (IHC) assays are. We have the Dako 22C3, we have the Dako 28-8, and then the Ventana assays and different clinical trials have used different versions of these at different expression levels. And regulatory bodies haven't really defined how to do the testing.  So, different sites and different physicians, and different practice groups are using different assays and may be interpreting differently. What this trial is telling us is that if you use the Dako 28-8 assay, you identify a much higher proportion of people who are positive for PD-L1, whether you use the 1% cut off or the 5% cut off, or the 10% cut off. Listen to these numbers. 28-8 at CPS of greater than 1, 70% with 28-8, and 49% with 22C3.  If you use the 10% cut-off, it's 13% if you use a 28-8 assay, but 7% for the 22C3 assay. So, that kind of throws into question how these assays are being used in daily practice. Well, some people may be, but a lot of people are not thinking about the cut-offs that were used in those clinical trials, especially when that comes to finding treatment options for our patients. And if we use the 28-8 assay, we're bound to find more patients who are PD-L1 positive, but that may not be the assay that the trials used in their validation cohort.  So, we may end up treating the wrong patients. But at the same time, if we use the other assay, we may be missing out on people who are PD-L1 positive. So, I think this is a call. This is a call for the field to harmonize how PD-L1 expression is defined. We need more data on inter-assay concordance so we can find the right drug and the right biomarker for the right patients.  This is a call for better prospective data and a call for harmonization between different assays and between different trials because this is an issue that is plaguing clinical practice today.  ASCO Daily News: Thank you! So, let's talk about advances in pancreatic cancer and Abstract 4155. The authors of this study note that pancreatic adenocarcinoma is the fourth leading cause of cancer deaths, with an increased incidence among patients younger than 50 years old. This study is a comparative analysis of the targetable landscape in KRAS mutant and wild-type pancreatic adenocarcinoma. So, can you tell us about it?  Dr. Shaalan Beg: The pancreatic cancer field has really suffered from a lack of effective treatment options, especially targeted treatment options and lack of effectiveness of immunotherapy for this disease.  Most patients still receive chemotherapy and we only have a couple of different combination treatments to help treat this disease, which is increasing in terms of the number of new cases and cancer-related deaths, and by some estimates may be the third leading cause of cancer-related deaths in the U.S.  A big reason that the survival for this cancer has not improved is because we don't have a lot of actionable or targetable mutations for this disease. One of the biomarkers that does have a corresponding treatment option is people who have a BRCA mutation. PARP inhibitors like olaparib have been approved for that group of patients, but the effectiveness of that medicine is modest for this disease, and we still have to see how much it's incorporated into daily practice.  But outside of the BRCA mutations and other DNA damage repair alterations, KRAS is really the most common mutation and there are new drugs that are out there to target KRAS. 90 plus percent of pancreas cancers have KRAS and if you think about it the other way, a small proportion of patients with pancreas cancer don't have KRAS.  So, what this abstract is looking to study is what are the characteristics of patients with pancreas cancer who don't have a mutation in KRAS, and can be the absence of KRAS actually be a biomarker for other mutations and other treatment strategies for pancreas cancer.  And this was a fairly large study of about 5,000 patients with pancreas cancer that use a commercial NGS assay. The same commercial NGS assay, who performed gene analysis, as well as full transcriptome RNA-seq, were retrospectively reviewed. And they found that people who had a KRAS wild-type tumor meaning no mutation in KRAS were much more likely to have mutations in HRD and in BRAF compared to those that had mutations in KRAS.  And then when you look at fusions, there was a much higher rate of NRG fusions. At the 2021 ASCO Annual Meeting, we heard some data on some new agents that are primarily targeting tumors that have fusions in NRG. And what this abstract is telling us is that the absence of a KRAS mutation may indirectly prompt us to look for other mutations, particularly fusions that may have additional treatment options available. So, this indirectly may be a biomarker of other actionable mutations.  The overall proportion of KRAS wild-type in this cohort was 21%. So higher than what I would have expected, but it's 21% out of 5000 cases that they evaluated and they really set out to see if young-onset pancreas cancer folks have a different proportion of KRAS wild-type and the proportion of KRAS wild-type in both young and typical onset pancreas cancer was really the same.  So, I believe this prompts us to think about pancreas cancer in 2 buckets, the KRAS wild-type, and KRAS mutated pancreas cancer. If we ever come across someone who has no detectable KRAS mutation, we should make sure that they have full transcriptomic analysis so we can look and get better coverage on those fusion changes that may have more treatment options associated with them.  ASCO Daily News: I'd like to follow up with a question about Abstract 4130. Investigators analyzed the molecular profile and clinical outcome of a cohort of patients with KRAS wild-type pancreatic ductal adenocarcinoma, what does this study tell us about the treatment implications for these patients?  Dr. Shaalan Beg: Yeah, so this was an abstract by Dr. Aakash Desai from the Mayo Clinic, and they went back and retrospectively reviewed patients who were seen at their center. And they looked for similar questions as the other abstract had done, but this was from a single center, and it seems like people had had multiple different assays performed.  In this cohort, they found 240 patients. That's 8%, had KRAS wild-type disease. So, they found 19 patients who did not have a KRAS mutation. And they went to see if there were any hints of differences or specific mutations between the patients with wild-type and mutated. And they found that the landscape of KRAS wild-type in pancreas cancer was very heterogeneous, and it was difficult for them to generalize or make any statements on what that could suggest.  A couple of things to think about for this study. Well, first of all, I think it's important for us to acknowledge that this particular space, the KRAS wild-type space, is gaining a lot of attention and is being recognized as an independent entity. So, you have multiple abstracts that have looked to study this group of patients.  I think the second study is different from the prior one in that it's a single-center study. And from what I understand, they may have used multiple assays. So, there was less standardization on the actual mutation testing that was being performed. And that has relevance for this specific question because we know that we need deeper transcriptomic analysis in order to be able to perform RNA-seq and really understand the fusions that may be driving cancer, and it's hard to know what the coverage for the mutations that were evaluated in the second abstract, which mutations were really being covered.  But if we take a couple of steps back and look at this, with the lens of where the pancreas cancer field is headed, again, I want to emphasize that how I view these coming together is that KRAS wild-type, pancreas cancer is becoming recognized as its own identity.  ASCO Daily News: Excellent! Well, thank you Dr. Beg for sharing your valuable insights with us today on the ASCO Daily News podcast. It's certainly an exciting time in GI oncology.  Dr. Shaalan Beg: Absolutely! Thank you so much for having me.  ASCO Daily News: And thank you to our listeners for your time today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you're enjoying the content on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts.  Disclosures:   Dr. Muhammad Shaalan Beg:  Employment: Science 37  Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine  Research Funding (Inst): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals  Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.     

Et cette semaine, faites du bruit (où que vous soyez) pour Odah & Dako !Et pour ne pas manquer les prochains épisodes de Montreux Comedy Edition Audio, abonnez-vous sur vos plateformes de podcast préférées !Suivez-nous partout !- YouTube : bit.ly/YoutubeMCF- Facebook : bit.ly/FacebookMCF- Instagram : bit.ly/InstagramMCF- Twitter : bit.ly/TwitterMCF- TikTok : bit.ly/TikTokMCFEt aussi sur montreuxcomedy.com Voir Acast.com/privacy pour les informations sur la vie privée et l'opt-out.

Kadet Oxibarren obra dügü aitzina irakurten. Oraikoan, bedakak eta üdako lanak deizkü aipatzen. Ürrentzean, Sü Aziak agerarazi züan libürüxkan berean arrahartürik züen hitzak emaiten dütügü.  Nous poursuivons la lecture de la belle ouvrage de Kadet Oxibar "Autrefois à Camou-Cihigue", avec les chapitres consacrés (entre autres) aux travaux des champs. En fin d'émission, nous reprenons quelques mots, tels que présentés dans le petit livret publié en son temps par Sü Azia.  Avec l'aide de l'Institut culturel basque et du Conseil départemental des Pyrénées-Atlantiques. En basque de Soule.   

Bienvenue dans Dyckson Discute. On est avec l'entier rappeur et humoriste Dako, nous allons parler improvisation et battle. C'est parti pour discuter création, créativité et tout ce qui s'en approche !

Dans ce 9ème épisode de Started From The Banlieue, nous avons reçu Dako.   On a pu échanger avec lui sur son parcours, sa carrière en duo avec Odah, la sortie de son premier E.P I.C.O, de ses inspirations rap, de sesdifférents projets sur Youtube et en télé et de plein d'autres choses que vous découvrirez tout le long de l'épisode.   Vous pouvez suivre son compte Instagram via ce lien :   Instagram : https://www.instagram.com/monsieur_dako Le nouveau clip de Fake issu de son premier E.P : https://youtu.be/NLVBk2Gpmsg   On vous laisse également nos réseaux si vous souhaitez être tenu au courant de l'actualité BeauxParleurs et des autres podcasts qu'on produit :    Instagram : https://www.instagram.com/beauxparleurs/Facebook : https://www.facebook.com/beauxparleurs.studio Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Farouk Dako, MD, MPH, discusses how radiology can use predictive analytics to positively impact health equity.

Text: Mga Hebrohanon 4:13-16. Speaker: Pastor Marven Joe "Zandro Joe Sr." Realista. Date: 12 August 2021. Main point: Kay si Jesus atong Dako nga Pangulong Pari, makatagamtam gayud kita sa saad nga kapahulayan. [Note: Watch this sermon on our Facebook page and YouTube channel or explore more resources on our website.]

durée : 00:02:36 - franceinfo: junior livres - par : Cécile Ribault Caillol - "Au secours je suis en Primaire" et "Au secours je suis au Collège", deux petits guides pour aborder en souriant la rentrée des jeunes élèves !

Dako dako meka, song matram keka, record badhalavdam pakka.. (Listen now)

Farouk Dako, MD, MPH, examines the importance of advancing radiology in underserved areas, along with the virtues of radiologic public health informatics.

Cette semaine, j'ai eu l'honneur de recevoir mon humoriste français préféré, celui dont je parle à chaque épisode de ce podcast : Kyan Khojandi ! On est revenu sur tout son parcours et on parlé d'humour en général ! On a donc abordé: - Le podcast en général et on profite pour recommander: Etienne Klein , le floodcast de Florent Bernard et Adrien Ménielle et les gens qui doutent de Fanny Ruwet - Son podcast « un bon moment »avec son acolyte Bruno Muschio alias Navo : les origines du podcast, ses envies pour la suite, ... on mentionne entre autre l'épisode spécial bloqué, celui de Roman Frayssinet, de Baptiste Lecaplain et Florent Bernard , de Julien Granel , de Florence Foresti, Yacine Et Dédo, Manu Payet, Natoo, Audrey Pirault, Cathy , Bigflo et oli , Haroun et Thomas Wiesel --> tous les épisodes sont disponibles ici : https://www.youtube.com/playlist?list=PLSkidoCR8oB3HDB-QSDlwGYbjeb5Ra4wG - L'émission « lol , tu ris tu sors » sur Prime Video : https://www.primevideo.com/detail/LOL-Qui-rit-sort/0OBE60IZD9EZIEWDFWNOGK90MD - Son enfance, ses parents et ses premières influences en humour - Le théâtre pendant ses études et ensuite ses études de théâtre - Du stress de la scène et des angoisses qu'on se crée - Le choc mental : https://www.youtube.com/results?search_query=choc+mental - Les cours Simon à Paris et les poèmes de Jean de Lafontaine « le chêne et le roseau » - Ses premières scènes de standup - Son premier spectacle « la bande annonce de ma vie » - Le spectacle « kheiron, Bun et Kyan mettent en pièce le comic hall/ montmatre Galabru » avec Kheiron, Bun Hay Mean - De son duo avec Navo et des qualités d'un bon co-auteur - La série Bref, l'écriture , ses épisodes préférés, les guests, … https://www.youtube.com/user/bref - L'écriture de son 2ème spectacle « pulsions » https://www.youtube.com/watch?v=u41ujNodvnM et le rodage entre autre aux soirées première fois de Yacine Belhousse et tout son procédé pour retravailler - Son sketch de l'addiction dans l'émission "derrière un micro" - La série Bloqués avec Orelsan et Gringe https://www.youtube.com/channel/UCd0V9SfenWqlPsTt5-AyN8A - La série Serge le Mytho avec Jonathan Cohen et on revient sur l'épisode « la malédiction des 1500 meufs » https://www.youtube.com/watch?v=v8D_SB2UC7Q&ab_channel=SergeleMytho - Son nouveau spectacle « une bonne soirée » - Les meilleurs endroits pour faire du standup , coucou au Bordel Comedy club de Montréal et le Kings of Comedy club d'ixelles en Belgique - Sa boite de production FKLG - L'émission soixante - ... On en a bien sûr profité pour name dropper et dire beaucoup de bien de : Roman Frayssinet, Baptiste Lecaplain, Freddy Gladieux, Navo, Franck Dubosc, Simon gouache, Sebastian Maniscalco, Pablo Francisco et Philippe Cobert , Bun Hay Mean, Alban Ivanov , Blanche Gardin, Haroun, Vérino, Antonia De Redinger, Adib Alkhalidey, Paul Mirabel, Bill Burr, Eddie Izzard, Dane cook, Florence Foresti , Ines Reg, Alexandre Astier, Pierre Thevenoux, Odah et Dako, Eric et Ramzy, Paul Dechavanne, Tanguy ,...

Kad rečenica može sadržavati sve ove pojmove/naredbe/zamolbe/želje? Pa samo u pms-u! :)Ponekad se i same zapitamo nije li pms samo izgovor za dane kad smo ustvari potpuno svoje . :DAko vam je ova rečenica bila smiješna niste u pms-u, a ako nije....idemo mi sad, čujemo se drugom prilikom. Boooook!Stay tuned!Sva pitanja, zahtjevi za suradnju i oglašavanje te sponzorstvo su dobrodošli. Kontaktirajte Belu i Miju na mail: rozekozepodcast@gmail.com Svoje komentare na ovu temu kao i prijedloge sljedećih tema koje bi voljeli da obradimo šaljite na:rozekozepodcast@gmail.cominstagram@rozekozepodcast

African Myths of Origin, Hwegbadja(Dako), The First King. IG: Everythingsjustphine --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/phines-jackson-jr7/support

Bahi koch nikol taru biko dako

W 79. Odcinku podcastu rozmawiamy o prognozie dotyczącej niemieckiego rynku okien i drzwi wejściowych. Od majowych zapowiedzi, że tamtejszą branżę czekają spadki wiele się zmieniło. Teraz analitycy z niemieckiego Verband Fenster + Fassade odnotowali poprawę koniunktury, a co za tym idzie prognoza uległa znacznej poprawie. Sprzedaż stolarki ma się poprawić w porównaniu z 2019 r., co w roku ma być . To kolejny dowód na to, że nasza branża w dobie pandemii radzi sobie dobrze. Omawiamy też polskie firmy, które coraz śmielej poczynają sobie na rynku Ameryki Północnej. Tym razem skupiamy się na Dako, które otworzyło firmowy salon w Ontario w Kanadzie i zdobywa nowych klientów w Kolumbii Brytyjskiej. Rozmawiamy tez o zapowiadanych nadchodzących zmianach niektórych ustaw wspierających rozwój mieszkalnictwa. Czy wpłynie to na wzrost zamówień na materiały budowlane, w tym na stolarkę?Nie zabrakło tez najświeższych informacji z branży stolarki, jak i Krótkiego Przeglądu Ekonomicznego, a tradycyjny suchar to absolutna perełka – został wymyślony na poczekaniu w trakcie trwania audycji! Miłego słuchania!W tym odcinku zapowiadamy też wyjątkowe wydarzenie - już w najbliższy czwartek (12 listopada) odbędzie się pierwszy Hyde Park Branżowiska, czyli prowadzona na żywo interaktywna audycja z udziałem naszych słuchaczy i widów! Startujemy o 17:30! Serdecznie zapraszamy do udziału.

In den kommenden Monaten und Jahren wird der KEP Markt neu aufgeteilt. Als Anwärter sind aktiv: Mittelständische oft regional tätige KEP Unternehmen, neue global agierende Plattformen die andere Branchen wie den Handel mit der KEP Branche verbinden, Konzerne als traditionelle Marktteilnehmer, deren (bisheriger) Schwerpunkt im KEP Markt und angrenzenden Logistikmärkten liegt. Für den heute oft mehr oder weniger stark autark agierenden Mittelstand wird sich entscheiden, ob er zukünftig fremdbestimmt oder souverän agieren kann. Traditionelle Konzerne und neue Plattformanbieter haben bereits den autarken Weg gewählt. Im Frühstückstalk sprechen Andreas Schumann, Florian Lange - bitkom - und Martin Erkel - DAKO - über das Spannungsfeld zwischen Autarkie und Fremdbestimmung und dazu welche Handlungsoptionen der Mittelstand hat.

A romantic bengali audio book series --- Send in a voice message: https://anchor.fm/sou00faru00e1v--ku00fandu/message

70. odcinek podcastu Branżowisko rozpoczynamy od największego producenta okien w Europie, czyli od firmy Eko-Okna. Po odejściu Michała Maciejewskiego w czerwcu 2020 r. branża zastanawiała się nad tym, kto zastąpi tego menadżera na stanowisku dyrektora handlowego firmy z Kornic. Właśnie poznaliśmy odpowiedź! Nową dyrektorką handlową w Eko-Oknach została Iwona Muszyńska. Funkcję tę objęła z początkiem września. Nowa menadżerka w Eko-Oknach obecna jest w branży stolarki od niemal dekady. Od 2012 r. aż do objęcia nowego stanowiska w firmie z Kornic związana była z nowosądeckim Dako.W tym epizodzie dużo mówimy również o comiesięcznym raporcie „Kondycja firm branży stolarki otworowej w Polsce” przygotowywanym przez Centrum Analiz Branżowych. Jak wynika z najnowszej jego odsłony, polska branża stolarki pod względem sprzedaży i nastrojów wyraźnie się ustabilizowała, a blisko 60 proc. menadżerów branży stolarki spodziewa się we wrześniu wyższej sprzedaży niż w sierpniu, a co trzeci zakłada, ze sprzedaż będzie na tym samym poziomie. To cieszy. Omawiamy też ciekawą inicjatywę Grupy Velux, która ma ambitny cel, by w ciągu 20 najbliższych lat stać się firmą zeroemisyjną. Ma to się stać we współpracy ze światową organizacją WWF, a już w najbliższej dekadzie światowy lider produkcji okien dachowych chce zredukować o połowę ilość odpadów u siebie i swoich dostawców, wdrożyć czujniki i automatykę w 1/3 swoich produktów oraz zorganizować alternatywne źródła energii dla swoich zakładów. Taka proekologiczność na szeroką skalę jest ewenementem nie tylko w branży stolarki. Trzymamy również rękę na branżowym pulsie, omawiając wejście na polski rynek włoskiej firmy Teleco, ekspansję Schüco w Stanach Zjednoczonych, jak i przypadek koronawirusa w firmie Vetrex. Ponadto sprawdzamy najnowsze doniesienia dotyczące targów branżowych, zarówno polskich, jak i zagranicznych. W dobie pandemii wiele imprez jest przesuwanych lub odwoływanych, więc będziemy się starali na bieżąco informować o aktualnych informacjach przekazywanych przez organizatorów. Nie zabrakło oczywiście najnowszych informacji o wynikach finansowych firm w ramach Krótkiego Przeglądu Ekonomicznego. Na koniec, a jakże, suchar wieńczący za każdym razem nasz podcast. Miłego słuchania!

KUNG NAGUSTUHAN MO ANG KAKAIBANG MGA KWENTONG ATING ITINAMPOK SA PART 1, ETO ANG KASUNOD. MGA WEIRDONG KWENTO NA DI MO TALAGA ALAM KUNG KAPUPULUTAN NGA BA NG ARAL. MULA SA PANULAT NI EROS ATALIA --- BE A MEMBER OF THIS CHANNEL!: https://www.youtube.com/channel/UCxRswj2N6mtuNpV36ej0IjA/join Support us by just watching an ad! Make sure you create an account first: https://utip.io/podcast #PinoyHorror #TagalogHorror #CreepyPasta BE PART OF OUR GROWING FAMILY!! Contribute and Earn from your stories! To apply please go to this link: https://rplg.co/BeAContributor Negative Comments will immediately be deleted and banned to the channel. We want to build positive community here. MUSIC LICENCED BY: EPIDEMICSOUND: https://rplg.co/453a2950 MUSICBED: https://www.musicbed.com/invite/MOXe4 THANK YOU SO MUCH FOR LISTENING! Follow, Follow! Facebook Page : https://www.facebook.com/storiesphpodcast/ Twitter : https://twitter.com/storiesph_ Listen to your favourite platform! Spotify: https://replug.link/spotifyph Anchor : https://replug.link/anchor Breaker : https://replug.link/breaker Castbox: https://replug.link/castbox iHeart Radio - https://replug.link/iheart Google Podcasts: https://replug.link/googlepodcasts Apple Podcasts: https://replug.link/applepodcasts Overcast: https://replug.link/overcast Pocket Casts: https://replug.link/pocketcasts RadioPublic: https://replug.link/radiopublic Stitcher Radio: https://replug.link/stitcher TuneIn Radio: https://replug.link/tunein SUPPORT US and get exclusive episodes and more!! Support on Patreon : https://www.patreon.com/bePatron?c=364916 Support on Anchor : https://anchor.fm/storiesph/support Donate Auphonic Credits for Better Sounding Podcast: https://auphonic.com/donate_credits?user=b1gang ABOUT US: We're Now STORIES PHILIPPINES PODCAST!! The Very First Pinoy Horror Podcast We started as Takutan Podcast pero nag-decide kami na there is more than just horror stories, there are stories out there na kahit hindi tungkol sa katatakutan ay talaga namang nakakamangha. Kaya ginawa namin ang Kwento at Takutan Podcast para mabigyan kayo nag kakaibang karanasan sa pakikinig nga mga kwento mula sa iba-ibang tao saan mang panig ng mundo. Maraming kababalaghan ang nababalot sa bawat sulok ng mundo. Maraming kwento ang naghihintay lamang na makwento. Iyan ang layunin ng Podcast na ito, ang maging daan upang ma-i-share ng bawat isa ang kani-kanilang mga karanasan at mai-kwento ito. Sinisikap naming magkaroon ng bagong Episode bawat linggo, tuwing Lunes o araw-araw! B1 Gang ba hanap mo? May podcast din kami diyan!: https://open.spotify.com/show/68kKagZQc8nxkKeaRly1Nq Maraming salamat mga ka-storya! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/storiesph/message Support this podcast: https://anchor.fm/storiesph/support

ANO BA TALAGA ANG MAYROON SA DAKO PA ROON? TUNGHAYAN NANAMAN ANG MGA KWENTONG PAMATAY! MULA SA PANULAT NI EROS ATALIA --- BE A MEMBER OF THIS CHANNEL!: https://www.youtube.com/channel/UCxRswj2N6mtuNpV36ej0IjA/join Support us by just watching an ad! Make sure you create an account first: https://utip.io/podcast #PinoyHorror #TagalogHorror #CreepyPasta BE PART OF OUR GROWING FAMILY!! Contribute and Earn from your stories! To apply please go to this link: https://rplg.co/BeAContributor Negative Comments will immediately be deleted and banned to the channel. We want to build positive community here. MUSIC LICENCED BY: EPIDEMICSOUND: https://rplg.co/453a2950 MUSICBED: https://www.musicbed.com/invite/MOXe4 THANK YOU SO MUCH FOR LISTENING! Follow, Follow! Facebook Page : https://www.facebook.com/storiesphpodcast/ Twitter : https://twitter.com/storiesph_ Listen to your favourite platform! Spotify: https://replug.link/spotifyph Anchor : https://replug.link/anchor Breaker : https://replug.link/breaker Castbox: https://replug.link/castbox iHeart Radio - https://replug.link/iheart Google Podcasts: https://replug.link/googlepodcasts Apple Podcasts: https://replug.link/applepodcasts Overcast: https://replug.link/overcast Pocket Casts: https://replug.link/pocketcasts RadioPublic: https://replug.link/radiopublic Stitcher Radio: https://replug.link/stitcher TuneIn Radio: https://replug.link/tunein SUPPORT US and get exclusive episodes and more!! Support on Patreon : https://www.patreon.com/bePatron?c=364916 Support on Anchor : https://anchor.fm/storiesph/support Donate Auphonic Credits for Better Sounding Podcast: https://auphonic.com/donate_credits?user=b1gang ABOUT US: We're Now STORIES PHILIPPINES PODCAST!! The Very First Pinoy Horror Podcast We started as Takutan Podcast pero nag-decide kami na there is more than just horror stories, there are stories out there na kahit hindi tungkol sa katatakutan ay talaga namang nakakamangha. Kaya ginawa namin ang Kwento at Takutan Podcast para mabigyan kayo nag kakaibang karanasan sa pakikinig nga mga kwento mula sa iba-ibang tao saan mang panig ng mundo. Maraming kababalaghan ang nababalot sa bawat sulok ng mundo. Maraming kwento ang naghihintay lamang na makwento. Iyan ang layunin ng Podcast na ito, ang maging daan upang ma-i-share ng bawat isa ang kani-kanilang mga karanasan at mai-kwento ito. Sinisikap naming magkaroon ng bagong Episode bawat linggo, tuwing Lunes o araw-araw! B1 Gang ba hanap mo? May podcast din kami diyan!: https://open.spotify.com/show/68kKagZQc8nxkKeaRly1Nq Maraming salamat mga ka-storya! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/storiesph/message Support this podcast: https://anchor.fm/storiesph/support

Odah et Dako sont deux super artistes de scène, auteurs, improvisateurs et mecs bien. J'ai de la chance de les connaître See acast.com/privacy for privacy and opt-out information.

Sulod kamo, ug atong pangitaon ang 'Mga Murag Korek' nga tubag sa kining 'Mga Murag Korek' nga pangutana:

To nasz pierwszy odcinek specjalny. W Branżowisku Extra rozmawiamy szerzej o naszych wrażeniach z Międzynarodowych Targów Budowlanych BATIMAT 2019 w Paryżu. Oceniamy, podsumowujemy, mówimy o nowościach rynkowych i produktach innowacyjnych. Omawiamy plusy i minusy paryskiej imprezy. Wybieramy również najciekawsze polskie stoiska targów.

Hai teman teman. Tahukan kamu digital marketing ini penting banget bagi pertumbuhan usaha kalian. Kali ini Co-Founder dari Dako Brand & Communication akan share pengalaman serta tipsnya. Stay tune ya...

Hey everyone we're back and stacked! Dako, Marc and jami join us in nursing an Easter Sunday hangover. Link in bio or it's “not feel good people” wherever you listen to your stuff.

Dako talks going blind and Breydon goes on a horrific journey of the mind

How have developments in research, drug development and management created new paradigms in the diagnosis and treatment of cancer and what this could mean for the future. Interviewees include: Dr Carlos Cordon-Cardo, a physician-scientist known widely for his research in experimental pathology and molecular oncology at the Icahn School of Medicine at Mount Sinai; Brian Dranka, Ph.D., Manager of Biology, Agilent Cell Analysis Division; Hans Christian Peterson, Director of Scientific Affairs at Dako, Agilent Pathology Solutions.

This week Max , Dako and Breydon talk Twin Peaks,Scrubs,Community,Punked and my man Turk Steel

Max,Aaron,Dako and Breydon talk there favorite consoles,Game of thrones,Fast and the furious and young maxes revenge

In this Ep Max,Dako and Breydon talk child hood peeing your pants twin peaks true detective season 2 and we get two amazing stories from two special guests

"En tout cas merci pour ces deux mois : on peut dire longue vie au roi !"

"En tout cas merci pour ces deux mois : on peut dire longue vie au roi !"

Florentin Pogba et Ludovic Giuly sont les invités de Téléfoot, l’After en compagnie de Bixente Lizarazu. Au sommaire de cette émission, des archives de Giuly (1:00), Interview de Noël Le Graët (4:00), Liza répond à vos questions (6:25), le Oui/Non de Thomas Mékhiche (9:06), les interactions en direct (13:55), l’Impro d’Odah et Dako (15:24).

Le début d'une nouvelle histoire d'amour, version hip-hop !

Le duo commente la prise de pouvoir de l'autoproclamé prince de la radio !

the gang talks Cosby, Alien, twin peaks and Breydon writes a book while Aaron advises him to go liquid. this ep is featuring Breydon, Max ,Dako,Aaron and Loren

Avec notre invité Baptiste Lecaplain, le duo imagine la fin du film en musique ! Mais tout ne se passe pas comme prévu, avec l'arrivée d'un troisième rappeur dans le game...

Notre timide mais sympathique auditeur a eu droit à un coup de pouce tout en freestyle de la part de notre duo !

Le duo, enfin de retour dans la team, a dû raconter les nouvelles reformes du Président, notamment pour les berges parisiennes...

Pour les amateurs de bière, le nom de Grimbergen évoque une brasserie belge renommée. Ce n’est pas de bière dont il sera question ce dimanche de Pentecôte 4 juin 2017, mais de la célébration du don de l’Esprit saint. Toutefois le lien entre la brasserie et la communauté des Prémontrés qui organise la célébration est avéré, puisque la bière fut jadis produite par les moines. Une communauté monastique qui s’établit là au XIIe siècle, en fut chassée à la Révolution française, avant de revenir s’installer au XIXe siècle. La basilique Saint-Servais de Grimbergen est considérée comme une des plus belles églises baroques du Brabant flamand même si elle n’a jamais été achevée comme en témoignent l’absence de flèche de clocher. En ce dimanche de la Pentecôte 4 juin 2017 de 11 h à 12 h, la communauté des Prémontrés accueille la célébration de l’Eurovision, diffusée sur RTS Un. Le père-abbé Erik De Sutter préside la messe. Côté choral, place à quatre chœurs: la Cantorij Sint-Cecilia, Basaltes et Dako, sous la direction de Maggy De Ridder, ainsi que le chœur grégorien de l’abbaye, dirigé par Gereon van Boesschoten. Et avec deux organistes, Kamiel D’hooghe à l’orgue à 41 registres et Adrien Fauconnier à l’orgue de chœur. Production: VRT (Belgique) Commentaire: Didier Croonenberghs (RTBF)

Le duo tente de percer le dernier mystère signé Trump...

Et le Président français le remercie avec des cadeaux... insolites !

Dako eats some chips featuring Dako, Breydon,Evan,Mark,and Max

Donald Trump, Afida Turner... qui a gagné au tabou du duo ?

Avec un voyage de noces à Center Park...

"On dit au revoir au réal', qui rejoint le Mad Mag !"

En ce lundi matin, Dako avait pour mission de séduire Valérie, tandis qu'Odah faisait tout pour l'en empêcher !

"Argument pour pécho : bouteille de Coca Zéro !"

Encore une sale histoire de politique, de chichas et de kebabs...

"On a freestylé... en mode Skyroulette !"

Un indice : Odah et Dako tentent de faire deviner un politicien !

"On a eu droit à un blind-test de bledard !"

Nos deux rappeurs font deviner des mots à des auditeurs.

Un standard qui marche et un nouveau record de Tupuduku : Odah et Dako avaient de la matière pour leur débrief quotidien !

En découvrant les listes d'En marche !, le maire de Pau claque la porte et plaque tout ! Petit bonus : le duo performe sous hélium !

Max puts the elderly out of there misery Dako talks his pocket pussy and fat puss is so in !

This is a gaming podcast built for you to ignore. Put us on in the background, we are your virtual friend. In this episode, we give our more in depth impressions of Zelda, share some tales from Hyrule, talk about what we want in the future, and how the Switch lets us live our lives how we want. We're still in pretty deep here. Just come hang out with us, we're cool, yo

Max and Breydon get into a fight, Dako and Max see a movie and Mark jacks it while farming

The Gang goes live in this super drunk fun episode and you get meet a bunch of new people featuring Kurby ,Burk,Braden HIll,Aaron,Mark,Steve,Dako,Max and Breydon LIVE AT THE OLD CHURCH!

Tonic smoothly transitions from a Jazzy Rap type flow, to the modern day R&B Toronto sound, Featuring a new upcoming artiste Khadi Dako.

A veces poner corazón en el escenario no es suficiente, ya que el verdadero premio reside en cuantos corazones eres capaz de subir a ese escenario. Volvemos más internacionales que nunca en esta nueva entrega de OnlyRealHH, vuestro programa sobre la cultura hip hop. En esta ocasión nos acompañarán los artistas colombianos Kin?o y Charako (Mafia Naezky), y los ecuatorianos Dako y Cinco Jota (Secta Selecta). Con ellos hablaremos sobre la vida y su trascendencia; sobre actualidad, sociedad, política etc; y por supuesto tampoco faltará la música, ya que presentaremos oficialmente en el programa el último LP de Kiño: "Más Parchao!" Además contamos con la inestimable ayuda de un equipo de colaboradores de ensueño, formado por Christian Capellán, representando "Rapdiación" desde República Dominicana; las hoy mansas e intelectuales preguntas de Bernardo HBK; y lamentablemente no hemos podido contactar con Ary finalmente, pero la semana que viene tendremos más "Real Hot News" que nunca, palabra.  También ponemos en juego un nuevo concurso esta semana, donde podréis llevaros a casa 2 entradas para el concierto del día 25 de febrero en la céntrica sala madrileña de "El perro de la parte de atrás del coche" totalmente gratis. Todo lo que tenéis que hacer para participar es compartir el cartel a través de nuestra página: www.facebook.com/onlyrealhh. Además tenemos doble concurso, ya que hasta el martes podréis ganar una copia del disco "Libre Expresión Vol.1" de Kiño, y todo lo que tendréis que hacer para poder llevároslo a casa será compartir vuestra canción favorita del artista en el cartel que hemos habilitado en nuestro facebook. ¡Nos oímos!

Olá mergulhadores ! Mais uma vez, mergulhamos profundamente (ui!) nos quadrinhos para discutir algo melhor que os próprios: sexo ! Nesse episódio, discutimos episódios de sexo nos quadrinhos, sejam eles eróticos, pornôs, de ação ou qualquer outro estilo ! Dudu Bandeira, Guilherme Smee, Fabiomesmo e Santiago Castro, acompanhados dos convidados especiais Annie O'Reilly, J.R. Weingartner Jr., e Mario Cesar Oliveira (http://www.masquemario.net/), comentam sexo nas hqs, em momentos marcantes ou não, bem construídos ou gratuitos, sempre com intervenções precisas do saudoso Alborghetti. (00:00:26) Abertura/Apresentação; (00:02:50) Monstro do Pântano de Moore e o pansexualismo na DC comics; (00:04:47) Outras obras sexuais de Alan Moore (e são muitas); (00:09:15) A sedução dos inocentes/Fredric Wertham; (00:15:42) Sexualidade e violência nos quadrinhos nos anos 80 e 90 - erros mais comuns; (00:19:00) Tina, Porra, Maurício e a Mulher-Hulk do Byrne; (00:25:26) Musas e cenas históricas de sexo (ou afins) nos quadrinhos: Hank Pym e Vespa/Angela e Spawn/ Superman e Big Barda/Kitty Pride e Colossus e outros; (00:40:14) Garth Ennis e suas HQs sexualmente polêmicas (sim, The Boys e Crossed); (00:51:18) Sexo: gratuidade ou não? (00:55:07) Indicações de quadrinhos com temática sexual; (01:01:24) Sexualidade hétero e homossexual nos quadrinhos Japoneses; (01:05:51) Batman e Robin na Feira da Fruta; musos nos quadrinhos e casais homossexuais; (01:14:36) Fechamento e considerações finais; (01:15:55) Apêndice: foda é... (01:18:03) Erramos, é foda. (01:22:38) Não gostou? Escuta essa! TRILHA SONORA (músicas sobre SEXOOO!): (0:00:00) Bobby Darin - Splish Splash (00:03:27) Kings Of Leon - Sex On Fire (00:08:41) Madonna - Erotica (00:13:36) George Michael - I Want Your Sex (Stereo Version) (00:18:21) Justin Timberlake - Sexy Back (00:22:20) The Adjustment Bureau 15- Fever (Adam Freeland Extended Remix) (00:29:35) James Brown - Sexmachine (00:34:52) Scissor Sisters - Sex and Violence (00:39:03) The Vaccines - Post Break-Up Sex (00:41:58) Deadpool - Robin Thicke - Blurred Lines Parody (00:46:58) Genival Lacerda - Severina Xique-Xique (00:50:12) Leonardo - Água de Côco (00:53:31) Tati Quebra Barraco - Fogão Dako (00:55:22) Rita Cadillac - É Bom para o Moral (00:58:44) Genival Lacerda - Tico Mia Eletronic Mix (01:00:36) Aviões do Forró - Lapada na Rachada (01:03:57) Ultraje a Rigor - Sexo (01:08:34) Grupo Capote e Odair Cabeça de Poeta - Feira da Fruta (01:11:02) Ultraje a Rigor - Sexo (Reprise) (01:15:39) Genival Lacerda - Tico Mia (Versão Clássica) (01:18:38) Rita Cadillac - É Bom para o Moral (Reprise) (01:22:00) Grupo Capote e Odair Cabeça de Poeta - Feira da Fruta (Reprise) LINKS: Orgia Disney: http://www.ep.tc/realist/74/12.html Edição de Sexo dos X-Men: http://goodcomics.comicbookresources.com/2011/07/19/comic-book-easter-eggs-new-sex-men-118-edition/ Blurred Lines por Deadpool: https://www.youtube.com/watch?v=06JvRsVZbpo Inspiração para a Druuna, de Paolo Eleuteri Serpieri (a modelo Ana Lima, na Playboy de 1989) NÃO RECOMENDÁVEL VER NO TRABALHO (NSFW): http://doubelieveinthehereafter.blogspot.com.br/2011/09/ana-lima-playboy-89-and-inspiration-for.html?zx=54448b52f7de4844 "Boy’s Love – Sem preconceito, sem limites" - Coletâneas - Guia Para Submissão de Contos: http://blyme-yaoi.com/main/2015/02/19/boys-love-sem-preconceito-sem-limites-coletanea-guia-para-submissao-de-contos/

Background: The aim of this retrospective analysis was to evaluate the impact of trastuzumab-based regimens on the survival of patients with HER2-overexpressing metastatic breast cancer (MBC). The study specifically focussed on the influence of the continuation of trastuzumab-based treatment despite tumor progression on survival. Patients and Methods: Patients with HER2 overexpressing MBC were included in this retrospective analysis. HER2 overexpression was determined by the immunohistochemical staining score (DAKO Hercep Test (TM)). Trastuzumab was applied at a loading dose of 4 mg/kg and a maintenance dose of 2 mg/kg. Results: Among 136 HER2 overexpressing patients (DAKO score 3+), 66 patients received first-line trastuzumab, 47 patients received trastuzumab as second-line therapy and 23 patients received trastuzumab beyond disease progression. There was no significant difference regarding the duration of trastuzumab-based treatment (first-line: 29.5 weeks vs. second-line: 25 weeks). Moreover, there was no difference in the response rate (first-line: 37.9% vs. second-line: 35.7%) or the median survival (p = 0.47 log rank). Patients who received >= 2 trastuzumab-based regimens for MBC survived significantly longer compared to those who had received only 1 regimen (>= 2 regimens: 62.4 months vs. 1 regimen: 38.5 months; p = 0.01 log rank). Conclusions: Trastuzumab is highly effective in the treatment of HER2 overexpressing MBC. Compared to historical controls, overall survival appears to be markedly prolonged, particularly in patients who received sequential trastuzumab-based treatment beyond disease progression.

Background: HER2 is overexpressed in 20 - 30% of breast cancers. Compared to chemotherapy alone, chemotherapy with trastuzumab improves clinical outcome in patients with HER2- positive metastatic breast cancer ( MBC). In general, HER2 status in a primary lesion predicts the status of metastases, so that biopsy of metastatic lesions appears unnecessary. Case Report: A 39- year old woman was diagnosed with primary breast cancer in November 2000. Using the method and scoring system of the DAKO Hercep Test, the tumor has shown low HER2 expression ( DAKO score 1+). After failure of several chemotherapy regimens for metastatic disease ( liver, skeletal), the patient underwent CT- guided needle biopsy of the liver which showed HER2 positive adenocarcinoma ( DAKO score 3+). In consequence, the patient was treated with vinorelbine ( 30 mg/ m(2) d1,8,15 q4w) and trastuzumab ( 4 mg/ kg loading dose, 2 mg/ kg weekly). During a treatment period of 4 months imaging results as well as tumor marker kinetics indicated an excellent response with sustained decrease of tumor markers. A retrospective analysis of the HER2 shed antigen in metastatic stage revealed excessively increased serum levels and supports HER2 overexpression observed in liver metastasis. The kinetics of the HER2 shed antigen during therapy for metastatic disease were found to be in phase with the kinetics of CEA and CA15- 3. Conclusion: This case report demonstrates that re- evaluation of the HER2 status may be helpful in single patients not sufficiently responding to treatment of metastatic disease. Determination of HER2 overexpression may be facilitated by a determination of the HER2 shed antigen level in peripheral blood.